Abstract:Background & aims: The new nomenclature of steatotic liver disease (SLD) was recently launched with sub-classifications of metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Herein, we aimed to evaluate the characteristics and long-term outcomes associated with these subgroups and the utility of non-invasive biomarkers. Methods: Using NHANES III (the third National Health and Nutrition Examination Survey) and linked mortality data, all adult participants with available ultrasonographic liver steatosis status were included. Those with viral hepatitis, incomplete data on alcohol consumption, cardiometabolic risk, and missing data that hindered Steatosis-associated Fibrosis Estimator (SAFE) score calculation were excluded. The characteristics of those without SLD (no steatosis on ultrasound), MASLD, MetALD, and ALD were compared. Overall survival (OS) was determined and SAFE score strata were applied to SLD subgroups. Results: A total of 9,939 participants were eligible; 64% had no SLD, while 30%, 2.3%, and 1% had MASLD, MetALD, and ALD, respectively. A higher proportion of men, as well as active smokers, was observed in the MetALD and ALD groups compared to the MASLD group. Diabetes was more prevalent in the MASLD group than in the MetALD and ALD groups. The ALD subgroup had significantly lower OS than the MASLD group (p = 0.004), but the MetALD did not (p = 0.165). SAFE score strata meaningfully differentiated OS of all SLD subgroups. Conclusions: MASLD accounted for the largest proportion of SLD. MetALD shared the characteristics of both MASLD and ALD. The ALD subgroup had a significantly lower OS than the MASLD subgroup but there was no difference between MetALD and MASLD. The SAFE score can be used to stratify long-term outcomes in all SLD subgroups. Impact and implications: "Steatotic liver disease (SLD)" is a recently introduced term covering three subgroups: MASLD (metabolic dysfunction-associated SLD), MetALD (MASLD with increased alcohol intake), and ALD (alcohol-related liver disease). We explored the characteristics and outcomes of these subgroups among the US population. We found that MASLD was far more common than MetALD and ALD, but all subgroups shared cardiometabolic risk factors. The ALD subgroup has the worst survival, pointing to the synergistic effect of alcohol and metabolic dysfunction. In addition, the SAFE (Steatosis-associated Fibrosis Estimator) score might be a useful non-invasive test to stratify long-term risk in all three SLD subgroups.

Long-term Outcomes and Risk Modifiers of MASLD Between Lean and Non-Lean Populations

Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study

S1927 Sounding the Alarm on Lean MASLD in US Adults: Insights From NHANES 2017-2020

Cardiovascular Morbidity and Mortality in Lean vs. Non-Lean MASLD: A Comprehensive Meta-Analysis

Update in lean metabolic dysfunction-associated steatotic liver disease

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

S2018 Lean Metabolic Dysfunction-Associated Steatotic Liver Disease: Higher Mortality and Complication Rates Compared to Higher BMI

Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Current status and future trends of the global burden of MASLD

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Prognostic outcomes of masld and obesity in acute myocardial infarction

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database